Signed in as:
filler@godaddy.com
Signed in as:
filler@godaddy.com
AI is revolutionizing pharmaceutical and diagnostic discovery and development by accelerating processes, reducing costs, and increasing precision across the value chain.
In early-stage drug discovery, AI enables rapid target identification, molecule design, and virtual screening.
In preclinical development, it improves toxicity prediction and optimizes pharmacokinetic profiling. For biomarker discovery and diagnostics,
AI integrates genomic, proteomic, and imaging data to identify predictive markers and drive companion diagnostic development.
During clinical trials, AI enhances patient stratification, streamlines site and protocol design, and improves recruitment and monitoring through predictive analytics.
In diagnostics, AI enhances image interpretation, enables liquid biopsy analysis, and supports clinical decision-making.
Finally, in the commercial and post-market phase, AI strengthens pharmacovigilance, generates real-world evidence, and supports forecasting and payer engagement.
Across all stages, AI’s ability to process and learn from complex data is driving more efficient, personalized, and successful therapeutic and diagnostic innovation.
DIAGEN has developed an operating system called OMNI to bring the utility and impact of artificial intelligence to life science discovery and research.
OMNI provides the structure, access, and technologies to supercharge your race to the clinic.
OMNI is a SaaS platform that enables AI to be applied to the life sciences. With a firm foundation from which to work, AI can develop into its potential.